This year’s San Antonio Breast Cancer Symposium (SABCS) will feature more than 20 posters and sessions focusing on invasive lobular carcinoma (ILC) over the course of the conference from Tuesday, December 6 through Saturday, December 10. The Lobular Breast Cancer Alliance (LBCA) is proud to be among the poster presenters sharing the findings from our survey last spring of individuals living with metastatic ILC. We will present our poster entitled Lobular Breast Cancer Alliance Inc. Survey of Individuals with Metastatic Invasive Lobular Carcinoma on the morning of Friday, December 9 in Poster Session 6. If you are attending SABCS in person please come by to visit us and see our poster!
Here is the list of all of the SABCS22 ILC-focused posters that you can visit in person of virtually. Posters submitted by members of the LBCA Scientific Advisory Board (SAB) and/or LBCA’s grantees are highlighted in bold blue font in the list of poster authors below.
Spotlight Poster Discussion Session 4: Wednesday 7am CT
Single Cell Approaches for Translational Research and Biomarker Discovery
PD4-07 Uncovering molecular heterogeneity of mixed ductal and lobular carcinoma using digital spatial profiling
Shah OS, Nasrazadani A, Atkinson JM, Kleer C, McAuliffe PF, Bhargava R, Reis-Filho J, Lucas PC, Lee AV, Oesterreich S. Integrative Systems Biology, School of Medicine, University of Pittsburgh; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center; University of Pittsburgh; Department of Pathology, University of Michigan; UPMC Magee-Womens Hospital; Memorial Sloan Kettering Cancer Center, New York, NY, USA; UPMC Hillman Cancer Center / NSABP Foundation; UPMC Hillman Cancer Center; University of Pittsburgh.
Poster Session 2: Wednesday 7am CT
Treatment – Adjuvant: Adjuvant Therapy – Other
P2-03-13 Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma
Metzger O, Parimi N, Siuliukina N, Zhang Y, Treuner K, Liefers G-J. Dana-Farber Cancer Institute; Biotheranostics, Inc; Biotheranostics, A Hologic Company; Department of Surgery, Leiden University Medical Center.
P2-03-16 Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
Clelland E, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Chien J, Schwartz CJ, Mukhtar R. University of California, San Francisco.
Tumor Cell and Molecular Biology: Microenvironment – Stromal-Epithelial Interactions
P2-21-01 Decoding inter- and intra-tumor heterogeneity in lobular breast cancer using spatial transcriptomics and clustering analysis
Serra M, Rediti M, Lifrange F, Venet D, Occelli N, Collet L, Vincent D, Rouas G, Craciun L, Larsimont D, Vikkula M, Duhoux FP, Rothé F, Sotiriou C. Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, University Hospital Center of Liege, Liege, Belgium; Medical Oncology Department, Centre Léon Bérard, Lyon, France; Laboratoire d’Anatomie Pathologique, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium; Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
P2-21-07 Exploring spatial correlations in Breast invasive Lobular Carcinoma subtypes using a novel CAF multiplex immunofluorescence panel
Batra H, Pandurengan RK, Ibarguen HP, McAllen SA, Ding Q, Sahin A, Wistuba I, Parra ER, Raso MG. UT MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center.
P2-21-08 Digital spatial profiling of RNA and protein in the invasive lobular breast cancer microenvironment
Bennett LB, Frerich C, Sahoo S, Lewis C, Raman I, Xu M, Chen G, Conzen SD. University of Texas Southwestern Medical Center.
Tumor Cell and Molecular Biology: Molecular Profiles
P2-23-15 Histologic, immunohistochemical and genomic comparison between classic Invasive lobular carcinomas and lobular-like invasive ductal carcinomas
da Silva EM, Basili T, Yu J, Blanco-Heredia J, Selenica P, Ye Q, da Cruz Paula A, Dopeso H, Marra A, Oesterreich S, Reis-Filho J, Bhargava R. Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Magee-Womens Hospital of UPMC; Memorial Sloan Kettering Cancer Center; University of Pittsburgh; Memorial Sloan Kettering Cancer Center, New York, NY, USA; UPMC Magee-Womens Hospital.
Special Poster Session: Wednesday, 9:45 am – 11am CT
HER2 Low: A Separate Entity?
HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated
factors and outcomes in an institutional series
Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Schwartz CJ, Mukhtar R. University of California, San Francisco; The University of Texas MD Anderson Cancer Center.
Poster Session 3: Wednesday 5pm CT
Prognostic and Predictive Factors – Prognostic Factors: Other
P3-05-04 Absence of lobular carcinoma in situ, a poor prognostic marker in invasive lobular carcinoma
Mouabbi J, Singareeka Raghavendra A, Christgen M, Hassan A, Hortobagyi GN, Tripathy D, Layman RM. The University of Texas MD Anderson Cancer Center; Medizinische Hochschule Hannover; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P3-05-08 Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma
Hensing WL, Xiu J, Korn WM, Graff SL, Kang i, Roussos Torres ET, Heeke AL, Davis AA, Bagegni NA, Clifton KK, Bose R, Ma CX, Ademuyiwa FO. St. Luke’s Cancer Institute, UMKC School of Medicine; Caris Life Sciences; Lifespan Cancer Institute, Brown University; Keck School of Medicine, University of Southern California; Levine Cancer Institute, Atrium Health; Washington University in St Louis School of Medicine; Washington University School of Medicine.
P3-05-35 The impact of parity and age of first full term pregnancy on the prevalence of invasive lobular carcinoma in patients with breast cancer
Van Baelen K, Nguyen H-L, Richard F, Vangoitsenhoven M, Floris G, Wildiers H, Punie K, Smeets A, Nevelsteen I, Amant F, Han S, Baert T, Neven P, Desmedt C. Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven; University Hospitals Leuven / RZ Tienen; University Hospitals Leuven; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; UZ Leuven; University Hospitals Leuven; Universitair Ziekenhuis Leuven, Leuven, Belgium; Laboratory for Translation Breast Cancer Research/KU Leuven.
P3-05-38 Biology and clinical course of lobular cancer in breast cancer (BC)
Singareeka Raghavendra A, Bassett R, Mouabbi J, Layman RM, Tripathy D. The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P3-05-40 Association of body mass index with clinicopathological features and survival in patients with primary ER+/HER2- invasive lobular breast cancer
Van Baelen K, Nguyen H-L, Richard F, Hamy A-S, Toussaint A, Reyal F, Salomon A, Dirix L, Vermeulen P, Wuyts H, Karsten M, Dordevic AD, Nader Marta G, de Azambuja E, Sotiriou C, Larsimont D, Amato O, Maetens M, De Schepper M, Geukens T, Han S, Baert T, Punie K, Wildiers H, Remmerie C, Smeets A, Nevelsteen I, Floris G, Biganzoli e, Neven P, Desmedt C. Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven; Institut Curie; Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium; Translational Cancer Research Unit, Center for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, GZA hospitals, Antwerp; Charité, Berlin; Academic Trials Promoting Team, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Academic Trials Promoting Team and Medical Oncology Department, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Laboratoire d’Anatomie Pathologique, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium; Clinical Trials Conduct Unit, Institut Jules Bordet; Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium & Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; University Hospitals Leuven; UZ Leuven; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; University Hospitals Leuven; Multidisciplinary Breast cancer Center (MBC), University Hospitals Leuven, Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) “L. Sacco” & DSRC, LITA Vialba campus, University of Milan, Milan, Italy; Universitair Ziekenhuis Leuven, Leuven, Belgium; Laboratory for Translation Breast Cancer Research/KU Leuven.
Tumor Cell and Molecular Biology: Animal Models
P3-08-10 Combining multiomics and histological assessment to identify patient derived xenograft models of invasive lobular carcinoma
Atkinson JM, Yates M, Brown DD, Hooda J, Bhargava R, Schiavini P, Zipeto M, Oesterreich S, Lee AV. University of Pittsburgh; UPMC Magee- Womens Hospital; Champions Oncology; UPMC Hillman Cancer Center.
Poster Session 4: Thursday 7am CT
Treatment – Advanced Disease Treatment: Advanced Therapy – Targeted
P4-01-24 Targeting receptor tyrosine kinases in overcoming tamoxifen resistance and dormancy in invasive lobular cancer
Ramaswamy B, Pramod N, Kulkarni A, Rima XY, Reátegui E, Shankar E, Majumder S. The Ohio State University Comprehensive Cancer Center; Cleveland Clinic; The Ohio State University.
Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers-Other
P4-02-04 Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance
Cani A, Dolce E, Turnbull A, Hu K, Liu C-J, Darga E, Robinson D, Wu Y-M, Thomas DG, Paoletti C, Tomlins S, Rae J, Udager A, Chinnaiyan A, Cobain EF, Hayes DF. University of Michigan; University of Michigan Medical School; University of Michigan Rogel Cancer Center; University of Michigan Comprehensive Cancer Center.
P4-02-25 Analysis of prognosis in different subtypes of invasive lobular carcinoma using a National Cancer Database Breast Cancer Registry of Japan
Adachi Y, Asaga S, Kumamaru H, Yamamoto Y, Imoto S, Jinno H. UT southwestern medical center; Department of Breast Surgery, Kyorin University School of Medicine; The University of Tokyo; Kumamoto University; Kyorin University Hospital; Department of Surgery, Teikyo University School of Medicine.
Epidemiology, Risk, and Prevention: Epidemiology – Population Studies
P4-03-11 Population-based survival outcomes of pure vs mixed invasive lobular breast carcinoma in Ontario, Canada
Lim D, Giannakeas V, Narod S, Metcalfe K. Women’s College Hospital; Women’s College Research Institute; University of Toronto.
Dr. David Lim will be presenting the ILC research that LBCA funded.
Treatment – Therapeutic Strategies: Neoadjuvant Chemotherapy
P4-06-04 Clinical outcomes of loco-regional HER2-positive invasive lobular carcinoma of the breast
Gaire S, Budhathoki P, Joshi U, Shah A, Choong GM, Yadav S. Department of Internal Medicine, Mount Sinai Hospital Chicago; Department of Internal Medicine, Bronxcare Health System; Department of Internal Medicine, Rochester General Hospital; Mayo Clinic.
Poster Session 5: Thursday 5pm CT
Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: For Targeted Therapies
P5-02-30 Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression
Mouabbi J, Singareeka Raghavendra A, Bassett R, Hassan A, Tripathy D, Layman RM. The University of Texas MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tumor Cell and Molecular Biology: Genomics
P5-14-01 Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial
Desmedt C, Nguyen H-L, Richard F, Linn S, Metzger O, Poncet C, Wesseling J, Hilbers F, Aalders K, Delorenzi M, Delaloge S, Pierga J0Y, Brain E, Vrijaldenhoven S, Neijenhuis PA, Van Baelen K, Maetens M, Rutgers E, Piccart M, Van ‘t Veer L, Viale G, Cardoso F. Laboratory for Translation Breast Cancer Research/KU Leuven; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Netherlands Cancer Institute, Amsterdam, Netherlands; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; NKI; Diakonessenhuis Utrecht; SIB Swiss Institute Bioinformatics; Institut Gustave Roussy, Villejuif, France; Institut Curie & Université Paris Cité; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Noordwest Ziekenhuisgroep; Alrijne Ziekenhuis; Department of Surgical Oncology, Netherlands Cancer Institute; Institut Jules Bordet – Université Libre de Bruxelles, Brussels, Belgium; The University of California, San Francisco CA, USA; European Institute of Oncology IRCCS, and University of Milan, Milan, Italy; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
Poster Session 6: Friday 7am-8:15am CT
Prognostic and Predictive Factors-Biomarkers Predicting Tx Response:Predictive Biomarkers for Chemo
P6-01-30 PgR levels and Ki67 expression of lobular carcinomas of the breast might indicate OncotypeDX testing to evaluate chemotherapy benefit
Markopoulos C, Sariyanni M, Karamargiou A, Antonopoulou Z, Tsoulos N. National Kapodistrian University of Athens; GeneKor Medical SA; Athens Medical Center.
Psychosocial, Quality of Life and Educational Aspects:Psychosocial, QOL & Educational Aspects-Other
P6-05-10 An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas
Oesterreich S, Pate L, Lee AV, Jankowitz RC, Derksen P, Mukhtar R, Metzger O, Sikora MJ, Li C, Sotiriou C, Ulaner G, Reis-Filho J, Davidson NE, Van Baelen K, Hutcheson L, Freeney S, Migyanka F, Turner C, Bear T, Desmedt C. University of Pittsburgh; UPMC Hillman Cancer Center; Abramsom Cancer Center, University of Pennsylvania; Division of Molecular Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands; University of California, San Francisco; Dana-Farber Cancer Institute; University of Colorado Anschutz Medical Campus; Fred Hutchinson Cancer Center; Institute Jules Bordet; Hoag Family Cancer Institute; Memorial Sloan Kettering Cancer Center, New York, NY, USA; University of Washington; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; LBCA; Lobular Ireland, ELBCC; Dynami Foundation; Lobular Breast Cancer UK; University of Pittsburgh; Laboratory for Translation Breast Cancer Research/KU Leuven.
P6-05-50 Lobular Breast Cancer Alliance Inc. Survey of Individuals with Metastatic Invasive Lobular Carcinoma
Hutcheson LB, Axelrod J, Camden A, Charlevoix DJ, Cushing TA, Jochelson MS, Kruse ML, Langdon T, Levine JK, McKay C, Metzger O, Mitchell- Daniels M, Mouabbi J, Neilsen BF. Lobular Breast Cancer Alliance Inc.; University of Colorado, Aurora CO; Memorial Sloan Kettering Cancer Center; Cleveland Clinic; Dana-Farber Cancer Institute; The University of Texas MD Anderson Cancer Center. LBCA Executive Director Laurie Hutcheson will be presenting this poster live in San Antonio.
Psychosocial, QOL, & Educational Aspects – Social & Education Issues: Disparities & Barriers to Care
P6-08-09 Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival
Kaur M, Patterson A, Molina-Vega J, Rothschild HT, Clelland E, Abel MK, Esserman LJ, Olopade OI, Mukhtar R. University of California, San Francisco; Center for Clinical Cancer Genetics & Global Health, Section of Hematology and Oncology, Department of Medicine, University of Chicago.
Ongoing Trials Posters
OCT Poster Session 2 – Wednesday 5pm CT
Ongoing Clinical Trials: Endocrine Therapy
OT2-01-01 Trial in progress: Clinical utility of Fluoroestradiol F18 PET/CT in metastatic breast cancer patients with ER-positive and HER2-negative primary lesions after progression on first line hormonal therapy
van de Ven S, Luo F, DiGregorio N, Fuentes-Alburo A, Tranquart F. GE Healthcare, Pharmaceutical Diagnostics.
Ongoing Clinical Trials: Estrogen Receptor Degrader
OT2-02-01 SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer
Turner NC, Vaklavas C, Calvo E, Garcia-Corbacho J, Incorvati J, Ruiz Borrego M, Twelves C, Armstrong A, Bermejo B, Hamilton E, Oliveira M, Ciruelos E, Kabos P, Patel MR, Borrell M, Burris H, de Paula B, Falcon A, Hernando C, Moreno I, O’Brien CS, Shagisultanova E, Victoria Ruiz I, Wang JS, Wei M, Brier T, Carroll D, Ciardullo C, Gibbons L, Irurzun-Arana I, Jack T, Kirova B, Klinowska T, Lindemann JPO, Maidment J, Mathewson A, Maudsley R, McEwen R, Morrow CJ, Sykes A, Baird RD. Institute of Cancer Research, Royal Marsden Hospital, London, UK; Huntsman Cancer Institute; START Madrid-CIOCC; Hospital Clinic Barcelona/IDIBAPs; Fox Chase Cancer Center; Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain; University of Leeds/Leeds Teaching Hospitals Trust, Leeds, United Kingdom; The Christie NHS Foundation Trust; Hospital Clínico Universitario de Valencia, Valencia, Spain; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA; Medical Oncology Department, Vall d’Hebron University Hospital and Breast Cancer Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain / Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; University of Colorado Denver, Aurora, CO, USA; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; Vall d’Hebron University Hospital, and Breast Cancer Group, Vall d’Hebron Institute of Oncology; Sarah Cannon Research Institute; University Department of Oncology, Cambridge Biomedical; Virgen del Rocio Hospital (Seville); Hospital Clínico Universitario de Valencia, Valencia, Spain; START Madrid-HM Centro Integral Oncológico Clara Campal (CIOCC), Hospital Universitario HM Sanchinarro, Madrid, Spain; The Christie NHS Foundation Trust, Manchester, UK; University of Colorado Anschutz Medical Center; Department of Medical Oncology (Hospital Clinic/IDIBAPs), Spain; Florida Cancer Specialists/Sarah Cannon Research Institute; Huntsman Cancer Institute; AstraZeneca, Cambridge, UK; AstraZeneca Translational Medicine, Early Oncology, Cambridge, United Kingdom; Oncology Patient Safety, Oncology R&D, AstraZeneca, Cambridge, UK; Late Development, Oncology R&D, AstraZeneca, Cambridge, UK; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK; Cancer Research UK Cambridge Centre.
